Astrazeneca PLC (AZN): Price and Financial Metrics
AZN Stock Summary
- Astrazeneca Plc's market capitalization of $125,243,520,000 is ahead of 98.25% of US-listed equities.
- In terms of twelve month growth in earnings before interest and taxes, Astrazeneca Plc is reporting a growth rate of 75.23%; that's higher than 84.91% of US stocks.
- In terms of volatility of its share price, AZN is more volatile than just 2.3% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Astrazeneca Plc, a group of peers worth examining would be AMGN, GSK, BA, SNY, and SAP.
- Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to www.astrazeneca.com.
AZN Stock Price Chart Interactive Chart >
AZN Price/Volume Stats
| Current price | $47.19 | 52-week high | $64.94 |
| Prev. close | $47.73 | 52-week low | $36.15 |
| Day low | $46.84 | Volume | 6,759,573 |
| Day high | $47.64 | Avg. volume | 11,384,514 |
| 50-day MA | $50.49 | Dividend yield | 3.9% |
| 200-day MA | $53.42 | Market Cap | 123.85B |
Astrazeneca PLC (AZN) Company Bio
AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $47.19 | $20.04 | -58% |
Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 33th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:
- Its compound free cash flow growth rate, as measured over the past 5.81 years, is -0.04% -- higher than merely 19.95% of stocks in our DCF forecasting set.
- The company has produced more trailing twelve month cash flow than 89.24% of its sector Healthcare.
- Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 13.7% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -59% |
| 1% | -59% |
| 2% | -58% |
| 3% | -58% |
| 4% | -58% |
| 5% | -57% |
Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See ABT, RMD, ZTS, HSIC, and DHR.
Latest AZN News From Around the Web
Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.
FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another DelayFibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday. |
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLUE, AZN and XOMNEW YORK, NY / ACCESSWIRE / March 2, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. |
SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmLOS ANGELES, CA / ACCESSWIRE / March 2, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U. Securities and Exchange Commission. |
European Officials Seek To Garner Support For AstraZeneca COVID-19 Shot: CNBCEuropean officials are under pressure to reverse restrictions on who can receive the Oxford-AstraZeneca Plc’s (NYSE: AZN) coronavirus vaccine and attract support for the shot, CNBC reports. Yesterday, France recommended the AstraZeneca shot to anyone under 75 (up from a previous age limit of 65), including those with pre-existing health problems. Speaking to the BBC, Carsten Watzl, head of the German Society for Immunology, urged Chancellor Angela Merkel to take the vaccine live on TV to show it’s safe. The European Medicines Agency approved the AZN-Oxford vaccine in January. Still, France and Germany’s health regulators, among others in Europe, only approved the vaccine for the under-65s, saying there was not enough evidence to prove the vaccine’s effectiveness in the higher age group.... |
CLASS ACTION UPDATE for AZN, XOM and IQDNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersNEW YORK, NY / ACCESSWIRE / March 2, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. |
AZN Price Returns
| 1-mo | -4.60% |
| 3-mo | -8.90% |
| 6-mo | -10.26% |
| 1-year | 6.46% |
| 3-year | 55.68% |
| 5-year | 95.10% |
| YTD | -3.82% |
| 2020 | 3.06% |
| 2019 | 35.58% |
| 2018 | 13.77% |
| 2017 | 33.10% |
| 2016 | -15.90% |
AZN Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching AZN
Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...